AROLDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 3.619
AS - Asia 3.162
EU - Europa 2.206
SA - Sud America 459
AF - Africa 84
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.542
Nazione #
US - Stati Uniti d'America 3.433
IT - Italia 954
VN - Vietnam 902
SG - Singapore 846
CN - Cina 590
BR - Brasile 346
HK - Hong Kong 310
RU - Federazione Russa 268
DE - Germania 230
IE - Irlanda 134
SE - Svezia 130
CA - Canada 118
GB - Regno Unito 94
BD - Bangladesh 93
FR - Francia 91
IN - India 87
KR - Corea 58
ES - Italia 51
FI - Finlandia 50
PL - Polonia 43
AR - Argentina 42
NL - Olanda 41
ID - Indonesia 39
MX - Messico 36
ZA - Sudafrica 35
IQ - Iraq 34
TR - Turchia 29
JP - Giappone 27
CH - Svizzera 26
PH - Filippine 24
PK - Pakistan 21
AT - Austria 20
SA - Arabia Saudita 19
UA - Ucraina 19
CO - Colombia 16
VE - Venezuela 16
UZ - Uzbekistan 15
EC - Ecuador 13
EG - Egitto 11
LT - Lituania 10
CZ - Repubblica Ceca 9
AU - Australia 8
CL - Cile 8
KE - Kenya 8
PT - Portogallo 8
AE - Emirati Arabi Uniti 7
CR - Costa Rica 7
ET - Etiopia 7
PY - Paraguay 7
IR - Iran 6
MA - Marocco 6
DO - Repubblica Dominicana 5
IL - Israele 5
NO - Norvegia 5
NP - Nepal 5
RO - Romania 5
AZ - Azerbaigian 4
JM - Giamaica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
BG - Bulgaria 3
HN - Honduras 3
JO - Giordania 3
MU - Mauritius 3
MY - Malesia 3
NI - Nicaragua 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
BH - Bahrain 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
DZ - Algeria 2
GT - Guatemala 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MM - Myanmar 2
MT - Malta 2
NG - Nigeria 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SV - El Salvador 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AL - Albania 1
BE - Belgio 1
FJ - Figi 1
GD - Grenada 1
GR - Grecia 1
LC - Santa Lucia 1
Totale 9.530
Città #
Ann Arbor 545
Singapore 474
Ashburn 404
San Jose 338
Milan 310
Hong Kong 279
Ho Chi Minh City 269
Hanoi 255
Dallas 210
Los Angeles 166
New York 144
Dublin 134
Frankfurt am Main 131
Hefei 119
Chandler 86
Beijing 84
Toronto 78
Fairfield 71
Santa Clara 69
Wilmington 68
Chicago 67
Woodbridge 62
Seoul 56
Houston 49
Rome 49
Council Bluffs 41
The Dalles 40
Lauterbourg 39
São Paulo 38
Seattle 36
Boardman 34
Haiphong 34
Buffalo 32
Shanghai 32
Jakarta 30
Munich 30
Warsaw 29
Columbus 27
Johannesburg 27
Kent 26
Orem 26
Princeton 24
Tokyo 24
Biên Hòa 22
Turin 22
Montreal 21
Poplar 21
Cambridge 20
Helsinki 20
Monza 20
Zurich 20
Atlanta 19
Lissone 19
Moscow 19
Da Nang 18
Chennai 17
Guangzhou 17
Nuremberg 17
Thái Nguyên 17
Turku 17
Ha Long 16
Hải Dương 16
London 16
Sesto San Giovanni 16
Baghdad 15
Desio 15
Ninh Bình 15
Phoenix 14
Romola 14
Stockholm 14
Amsterdam 13
Denver 13
Rio de Janeiro 13
Seveso 13
Lawrence 12
Quận Bình Thạnh 12
Tashkent 12
Altamura 11
Bologna 11
Brooklyn 11
Bắc Ninh 11
Lappeenranta 11
Can Tho 10
Mexico City 10
Riyadh 10
Salt Lake City 10
Querétaro 9
Bogotá 8
Bắc Giang 8
Como 8
Curitiba 8
Dhaka 8
Dong Ket 8
Erbil 8
Genoa 8
Jacksonville 8
Lesmo 8
Quận Một 8
Quận Phú Nhuận 8
San Diego 8
Totale 5.859
Nome #
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 461
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 420
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 391
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 384
Idiopathic erythrocytosis: a germline disease? 381
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 378
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 351
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 334
Chronic myeloid leukemia: Second-line drugs of choice 331
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 328
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 320
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 311
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 291
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 282
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 268
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 267
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 267
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 263
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 258
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy 251
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 245
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 244
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 242
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 235
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 226
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 225
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 221
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 221
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 217
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 215
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 189
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 147
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 140
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) 136
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors 120
Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options 107
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution 6
Totale 9.673
Categoria #
all - tutte 27.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.932


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 0 0 61
2021/2022295 52 36 48 38 14 23 4 8 7 10 17 38
2022/2023421 37 117 37 27 24 62 29 8 35 12 26 7
2023/2024650 14 20 30 27 61 175 96 25 67 42 26 67
2024/20251.883 56 141 88 76 119 88 113 69 170 323 213 427
2025/20265.581 887 456 456 708 495 222 769 223 340 462 224 339
Totale 9.673